Vectors based on modified vaccinia ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Hessel, Annett ^a   Schwendinger, Michael ^a   Holzer, Georg W ^a   Orlinger, Klaus K ^a   Coulibaly, Sogue ^a   Savidis Dacho, Helga ^a   Zips, Marie Luise ^a   Crowe, Brian A ^a   Kreil, Thomas R ^a   Ehrlich, Hartmut J ^a   Barrett, P Noel ^a   Falkner, Falko G ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HERPESVIRUS VECTOR; IMMUNOGLOBULIN G; INFLUENZA VIRUS HEMAGGLUTININ; LIVE ATTENUATED MODIFIED VACCINIA ANKARA VECTOR; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS VECTOR; HEMAGGLUTININ; VACCINE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHICKEN; CLADISTICS; CONTROLLED STUDY; CROSS PROTECTION; DRUG SCREENING; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; GENE INSERTION SEQUENCE; INFLUENZA A; INFLUENZA VIRUS A H5N1; LYMPHOCYTE FUNCTION; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SINGLE DRUG DOSE; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT; VIRUS STRAIN; ANIMAL; BIOSYNTHESIS; CHEMISTRY; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; SPECIES DIFFERENCE; VACCINATION; VACCINIA VIRUS;

MUS; ORTHOMYXOVIRIDAE;

ANIMALS; CROSS PROTECTION; GENETIC VECTORS; HEMAGGLUTININS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; MICE; SPECIES SPECIFICITY; VACCINATION; VACCINES; VACCINIA VIRUS;

EID: 79551569177     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016247     Document Type: Article

References (40)

1. Wright PF, Neumann G, Kawaoka Y (2007) Orthomyxoviruses. In: Knipe DM, Howley P, eds. Fields Virology. 5th Edition ed: Lipincott Williams & Wilkins. pp 1728-1733.
2. WHO website. Available: http://www.who.int/csr/disease/avian_influenza/country/cases_table_2010_12_09/en/index.html. Accessed 2010 Dec 29.
3. Kistner O, Howard MK, Spruth M, Wodal W, Bruhl P, et al. (2007) Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25: 6028-6036.
4. Murakami S, Iwasa A, Iwatsuki-Horimoto K, Ito M, Kiso M, et al. (2008) Crossclade protective immunity of H5N1 influenza vaccines in a mouse model. Vaccine 26: 6398-6404.
5. Crevar CJ, Ross TM (2008) Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. Virol J 5: 131.
6. Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, et al. (2008) Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 3: e1501.
7. Mayr A, Hochstein-Mintzel V, Stickl H (1975) Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA. Infection 3: 9.
8. Mayr A, Danner K (1978) Vaccination against pox diseases under immunosuppressive conditions. Dev Biol Stand 41: 225-234.
9. Sutter G, Moss B (1992) Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A 89: 10847-10851.
10. Carroll MW, Moss B (1997) Poxviruses as expression vectors. Curr Opin Biotechnol 8: 573-577.
11. Kreijtz JH, Suezer Y, van Amerongen G, de Mutsert G, Schnierle BS, et al. (2007) Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis 195: 1598-1606.
12. Kreijtz JH, Suezer Y, de Mutsert G, van Amerongen G, Schwantes A, et al. (2009) MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. PLoS One 4: e7790.
13. Kreijtz JH, Suezer Y, de Mutsert G, van den Brand JM, van Amerongen G, et al. (2009) Preclinical evaluation of a modified vaccinia virus Ankara (MVA)- based vaccine against influenza A/H5N1 viruses. Vaccine 27: 6296-6299.
14. Kreijtz JH, Suezer Y, de Mutsert G, van den Brand JM, van Amerongen G, et al. (2009) Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J Infect Dis 199: 405-413.
15. Mayrhofer J, Coulibaly S, Hessel A, Holzer GW, Schwendinger M, et al. (2009) Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. J Virol 83: 5192-5203.
16. Hessel A, Schwendinger M, Fritz D, Coulibaly S, Holzer GW, et al. (2010) A Pandemic Influenza H1N1 Live Vaccine Based on Modified Vaccinia Ankara Is Highly Immunogenic and Protects Mice in Active and Passive Immunizations. PLoS One 5.
17. Wyatt LS, Shors ST, Murphy BR, Moss B (1996) Development of a replicationdeficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14: 1451-1458.
18. Yuen L, Moss B (1987) Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes. Proc Natl Acad Sci U S A 84: 6417-6421.
19. Holzer GW, Gritschenberger W, Mayrhofer JA, Wieser V, Dorner F, et al. (1998) Dominant host range selection of vaccinia recombinants by rescue of an essential gene. Virology 249: 160-166.
20. Scheiflinger F, Dorner F, Falkner FG (1998) Transient marker stabilisation: a general procedure to construct marker-free recombinant vaccinia virus. Arch Virol 143: 467-474.
21. Holzer GW, Remp G, Antoine G, Pfleiderer M, Enzersberger OM, et al. (1999) Highly efficient induction of protective immunity by a vaccinia virus vector defective in late gene expression. J Virol 73: 4536-4542.
22. Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, et al. (1998) Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16: 960-968.
23. Reed L, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27: 493-497.
24. Bui HH, Peters B, Assarsson E, Mbawuike I, Sette A (2007) Ab and T cell epitopes of influenza A virus, knowledge and opportunities. ProcNatlAcadSciUSA 104: 246-251.
25. WHO website. Available: http://www.who.int/csr/disease/avian_influenza/guidelines/nomenclature/en/index.html. Accessed 2010 Dec 29.
26. Antoine G, Scheiflinger F, Dorner F, Falkner FG (1998) The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244: 365-396.
27. Himly M, Foster DN, Bottoli I, Iacovoni JS, Vogt PK (1998) The DF-1 chicken fibroblast cell line: transformation induced by diverse oncogenes and cell death resulting from infection by avian leukosis viruses. Virology 248: 295-304.
28. Yamada S, Suzuki Y, Suzuki T, Le MQ, Nidom CA, et al. (2006) Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature 444: 378-382.
29. Teijaro JR, Verhoeven D, Page CA, Turner D, Farber DL (2010) Memory CD4 T cells direct protective responses to influenza virus in the lungs through helperindependent mechanisms. J Virol 84: 9217-9226.
30. Epstein SL, Lo CY, Misplon JA, Bennink JR (1998) Mechanism of protective immunity against influenza virus infection in mice without antibodies. J Immunol 160: 322-327.
31. Boon AC, Webby RJ (2009) Antigenic cross-reactivity among H5N1 viruses. Curr Top Microbiol Immunol 333: 25-40.
32. Wu WL, Chen Y, Wang P, Song W, Lau SY, et al. (2008) Antigenic profile of avian H5N1 viruses in Asia from 2002 to 2007. J Virol 82: 1798-1807.
33. Hoffmann E, Lipatov AS, Webby RJ, Govorkova EA, Webster RG (2005) Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc Natl Acad Sci U S A 102: 12915-12920.
34. Ha Y, Stevens DJ, Skehel JJ, Wiley DC (2001) X-ray structures of H5 avian and H9 swine influenza virus hemagglutinins bound to avian and human receptor analogs. Proc Natl Acad Sci U S A 98: 11181-11186.
35. Boltz DA, Douangngeun B, Phommachanh P, Sinthasak S, Mondry R, et al. (2010) Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic. J Gen Virol 91: 949-959.
36. Su Y, Yang HY, Zhang BJ, Jia HL, Tien P (2008) Analysis of a point mutation in H5N1 avian influenza virus hemagglutinin in relation to virus entry into live mammalian cells. Arch Virol 153: 2253-2261.
37. Lim AP, Wong SK, Chan AH, Chan CE, Ooi EE, et al. (2008) Epitope characterization of the protective monoclonal antibody VN04-2 shows broadly neutralizing activity against highly pathogenic H5N1. Virol J 5: 80-85.
38. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324: 246-251.
39. Crowe SR, Miller SC, Woodland DL (2006) Identification of protective and non-protective T cell epitopes in influenza. Vaccine 24: 452-456.
40. Zhong W, Reche PA, Lai CC, Reinhold B, Reinherz EL (2003) Genome-wide characterization of a viral cytotoxic T lymphocyte epitope repertoire. J Biol Chem 278: 45135-45144.